AstraZeneca halts late-stage lung cancer trial of Volrustomig
AZN Astrazeneca plc
$156.45 -0.50%
View chart & analysis → 
- 1AstraZeneca (AZN) halts late-stage trial of Volrustomig in lung cancer
- 2Accepts independent data monitoring committee recommendation that combining with chemotherapy is unlikely to improve survival versus existing treatment
- 3Second pipeline setback in just over a month... shares rose up to 2% intraday on Monday
This 3-line summary is compiled from the report below.
Proactive +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다